193 related articles for article (PubMed ID: 30253376)
1. The Valgent4 protocol: Robust analytical and clinical validation of 11 HPV assays with genotyping on cervical samples collected in SurePath medium.
Bonde J; Ejegod DM; Cuschieri K; Dillner J; Heideman DAM; Quint W; Pavon Ribas MA; Padalko E; Christiansen IK; Xu L; Arbyn M
J Clin Virol; 2018 Nov; 108():64-71. PubMed ID: 30253376
[TBL] [Abstract][Full Text] [Related]
2. Clinical performance of the HPV-Risk assay on cervical samples in SurePath medium using the VALGENT-4 panel.
Heideman DAM; Xu L; Hesselink AT; Doorn S; Ejegod DM; Pedersen H; Quint WGV; Bonde J; Arbyn M
J Clin Virol; 2019 Dec; 121():104201. PubMed ID: 31629967
[TBL] [Abstract][Full Text] [Related]
3. Clinical and Analytical Performance of the BD Onclarity HPV Assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework.
Bonde JH; Pedersen H; Quint W; Xu L; Arbyn M; Ejegod DM
J Clin Microbiol; 2020 Jan; 58(2):. PubMed ID: 31723012
[TBL] [Abstract][Full Text] [Related]
4. Clinical validation of the Cobas 4800 HPV assay using cervical samples in SurePath medium under the VALGENT4 framework.
Ejegod DM; Hansen M; Christiansen IK; Pedersen H; Quint W; Xu L; Arbyn M; Bonde J
J Clin Virol; 2020 Jul; 128():104336. PubMed ID: 32446166
[TBL] [Abstract][Full Text] [Related]
5. VALGENT: A protocol for clinical validation of human papillomavirus assays.
Arbyn M; Depuydt C; Benoy I; Bogers J; Cuschieri K; Schmitt M; Pawlita M; Geraets D; Heard I; Gheit T; Tommasino M; Poljak M; Bonde J; Quint W
J Clin Virol; 2016 Mar; 76 Suppl 1():S14-S21. PubMed ID: 26522865
[TBL] [Abstract][Full Text] [Related]
6. Clinical validation of full genotyping CLART® HPV4S assay on SurePath and ThinPrep collected screening samples according to the international guidelines for human papillomavirus test requirements for cervical screening.
Ejegod DM; Lagheden C; Bhatia R; Pedersen H; Boada EA; Sundström K; Cortés J; Josë FXB; Cuschieri K; Dillner J; Bonde J
BMC Cancer; 2020 May; 20(1):396. PubMed ID: 32375689
[TBL] [Abstract][Full Text] [Related]
7. Clinical and analytical performance of the CLART HPV 4S assay with SurePath screening samples from the Danish cervical cancer screening program using the VALGENT framework.
Ejegod DM; Pedersen H; Quint W; Xu L; Arbyn M; Bonde JH
J Virol Methods; 2021 Jun; 292():114118. PubMed ID: 33766660
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Clinical Performance of the HPV-Risk Assay Using the VALGENT-3 Panel.
Polman NJ; Oštrbenk A; Xu L; Snijders PJF; Meijer CJLM; Poljak M; Heideman DAM; Arbyn M
J Clin Microbiol; 2017 Dec; 55(12):3544-3551. PubMed ID: 29021152
[TBL] [Abstract][Full Text] [Related]
9. Using the VALGENT-3 framework to assess the clinical and analytical performance of the RIATOL qPCR HPV genotyping assay.
Benoy I; Xu L; Vanden Broeck D; Poljak M; Oštrbenk Valenčak A; Arbyn M; Bogers J
J Clin Virol; 2019 Nov; 120():57-62. PubMed ID: 31569008
[TBL] [Abstract][Full Text] [Related]
10. Clinical Evaluation of INNO-LiPA HPV Genotyping
Xu L; Padalko E; Oštrbenk A; Poljak M; Arbyn M
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30208597
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
Oštrbenk A; Xu L; Arbyn M; Poljak M
J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
[TBL] [Abstract][Full Text] [Related]
12. Clinical and Analytical Performance of the Onclarity HPV Assay Using the VALGENT Framework.
Cuschieri K; Geraets DT; Moore C; Quint W; Duvall E; Arbyn M
J Clin Microbiol; 2015 Oct; 53(10):3272-9. PubMed ID: 26246482
[TBL] [Abstract][Full Text] [Related]
13. Validation of EUROArray HPV test using the VALGENT framework.
Viti J; Poljak M; Oštrbenk A; Bhatia R; Alcañiz Boada E; Cornall AM; Cuschieri K; Garland S; Xu L; Arbyn M
J Clin Virol; 2018 Nov; 108():38-42. PubMed ID: 30223253
[TBL] [Abstract][Full Text] [Related]
14. VALHUDES: A protocol for validation of human papillomavirus assays and collection devices for HPV testing on self-samples and urine samples.
Arbyn M; Peeters E; Benoy I; Vanden Broeck D; Bogers J; De Sutter P; Donders G; Tjalma W; Weyers S; Cuschieri K; Poljak M; Bonde J; Cocuzza C; Zhao FH; Van Keer S; Vorsters A
J Clin Virol; 2018 Oct; 107():52-56. PubMed ID: 30195193
[TBL] [Abstract][Full Text] [Related]
15. Assessment of the Roche Linear Array HPV Genotyping Test within the VALGENT framework.
Xu L; Oštrbenk A; Poljak M; Arbyn M
J Clin Virol; 2018 Jan; 98():37-42. PubMed ID: 29241150
[TBL] [Abstract][Full Text] [Related]
16. Clinical performance of the novel full-genotyping OncoPredict HPV Quantitative Typing assay using the VALGENT framework.
Cocuzza CE; Dhillon SK; Martinelli M; Giubbi C; Njoku RC; Bhatia R; Cuschieri K; Arbyn M
Int J Cancer; 2024 Feb; 154(3):538-547. PubMed ID: 37855030
[TBL] [Abstract][Full Text] [Related]
17. Clinical validation of the HPVIR high-risk HPV test on cervical samples according to the international guidelines for human papillomavirus DNA test requirements for cervical cancer screening.
Gustavsson I; Aarnio R; Myrnäs M; Hedlund-Lindberg J; Taku O; Meiring T; Wikström I; Enroth S; Williamson AL; Olovsson M; Gyllensten U
Virol J; 2019 Aug; 16(1):107. PubMed ID: 31438976
[TBL] [Abstract][Full Text] [Related]
18. Clinical Performance of the Full Genotyping Agena MassARRAY HPV Assay Using SurePath Screening Samples within the VALGENT4 Framework.
Pedersen H; Ejegod DM; Quint W; Xu L; Arbyn M; Bonde J
J Mol Diagn; 2022 Apr; 24(4):365-373. PubMed ID: 35123039
[TBL] [Abstract][Full Text] [Related]
19. Performance of a Cartridge-Based Assay for Detection of Clinically Significant Human Papillomavirus (HPV) Infection: Lessons from VALGENT (Validation of HPV Genotyping Tests).
Cuschieri K; Geraets D; Cuzick J; Cadman L; Moore C; Vanden Broeck D; Padalko E; Quint W; Arbyn M
J Clin Microbiol; 2016 Sep; 54(9):2337-42. PubMed ID: 27385707
[TBL] [Abstract][Full Text] [Related]
20. Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities.
Schmitt M; Depuydt C; Benoy I; Bogers J; Antoine J; Arbyn M; Pawlita M;
J Clin Microbiol; 2013 May; 51(5):1458-64. PubMed ID: 23447632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
